Halozyme Therapeutics (HALO) FY2017 results: revenue $317 million, up 115.8% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $317 million for fiscal 2017, the year ended 31 December 2017, up 115.8% on the year before. Net income was $63 million, and diluted earnings per share $0.45. The figures are the company's own, from the 10-K it filed with the SEC on 20 February 2018.
Revenue
$317 million
+115.8% on the year
FY2010FY2017
Operating margin
25.6%
-56.7% a year earlier
FY2010FY2017
Net income
$63 million
FY2010FY2017
Diluted EPS
$0.45
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
317
147
135
+115.8%
Cost of revenue
31.2
33.2
29.2
-6.2%
Gross profit
285
113
106
+151.5%
Gross margin
90.2%
77.4%
78.3%
Research and development
151
151
93.2
-0.1%
Selling, general and administrative
53.8
45.9
40.0
+17.4%
Operating income
81.0
-83.2
-27.5
Operating margin
25.6%
-56.7%
-20.3%
Interest expense
22.0
20.0
5.2
+10.0%
Pre-tax income
61.6
-102
-32.2
Income tax
-1.4
1.2
0.0
Effective tax rate
-2.2%
n/a
n/a
Net income
63.0
-103
-32.2
Net margin
19.9%
-70.2%
-23.9%
Diluted EPS
$0.45
-$0.81
-$0.25
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
134
-50.4
-37.1
Capital expenditure
1.4
3.1
2.4
-57.0%
Free cash flow
133
-53.5
-39.4
Free cash flow margin
41.9%
-36.5%
-29.2%
Cash from investing
-164
-76.8
5.9
Cash from financing
132
151
13.1
-12.6%
Depreciation and amortisation
2.2
2.4
1.7
-10.3%
Share-based compensation
30.7
25.6
20.8
+19.9%
Buybacks
0.0
n/a
n/a
Diluted shares, weighted
139m
128m
127m
+8.7%
Shares outstanding at period end
143m
130m
128m
+10.3%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
208
-32.5
43.0
Debt
202
217
49.8
-6.6%
Other liabilities
109
77.4
89.0
+41.2%
Total liabilities and equity
520
262
182
+98.8%
Fixed assets
3.5
4.3
3.9
-17.4%
Investments
300
138
65.0
+117.4%
Cash and equivalents
169
66.8
43.3
+152.7%
Receivables
22.1
15.7
32.4
+41.2%
Inventory
5.1
14.6
9.5
-64.8%
Other assets
19.9
22.0
27.6
-9.3%
Total assets
520
262
182
+98.8%
10-K for the year ended 31 December 2017, filed 20 February 2018: the filing.